← All tickers

Is SRPT Worth Buying in 2026?

Sarepta Therapeutics,, Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-06-14

Here’s whether Sarepta Therapeutics,, Inc. Common Stock (SRPT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.

🔴
Bearish

Positives: RSI 38 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-3.89% over 10 days); weak 1-year return of -59.0%; 3-month momentum negative (-8.1%). Currently 59.8% off its 52-week high. Score: -5/7.

Ready to act on this? 📈 Trade on Webull

SRPT is trading below its 200-day MA ($19.75) — a key warning sign the longer-term trend is under pressure. An RSI of 37.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -59.0% compares to +22.9% for SPY (trailed the market by 81.8%). The current 59.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $4,103 today
vs. S&P 500 (SPY) — same period trailed market by 81.8%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✗Above 200-day MA ($19.75)
✗Above 50-day MA ($19.30)
✓RSI(14) neutral zone (30–70) — currently 37.6
✗Positive return (-59.0%)
!Within 10% of period high (−59.8%)
Period Range $15.31
$10.42 $38.09
RSI (14) 37.6
0 · OversoldOverbought · 100

Key Metrics

Price$15.31
Period Return-59.0%
Period High$38.09
Period Low$10.42
Drawdown−59.8%
MA-50$19.30
MA-200$19.75
RSI (14)37.6
Avg Volume (30d)3.0M
vs. SPYtrailed by 81.8%
Return Rank#1122 of 1246

Trade SRPT

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers